H.C. Wainwright has recently initiated Rhythm Pharmaceuticals Inc (RYTM) stock to Buy rating, as announced on September 18, 2024, according to Finviz. Earlier, on September 17, 2024, JMP Securities had initiated the stock to Mkt Outperform, setting a price target of $64. BofA Securities also reduced Neutral rating with a price target of $42. Additionally, Morgan Stanley raised their rating on December 19, 2023, with a target price of $55. BofA Securities analysts, in their report published on August 1, 2023, also raised Buy rating and set a price target of $27 for Rhythm Pharmaceuticals Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Rhythm Pharmaceuticals Inc (RYTM) Stock Trading Recap
On Friday, Rhythm Pharmaceuticals Inc (RYTM) stock saw a decline, ending the day at $52.8 which represents a decrease of $-1.75 or -3.21% from the prior close of $54.55. The stock opened at $54.55 and touched a low of $52.47 during the day, reaching a high of $54.55. The volume of shares traded was 0.63 million exceeding the average volume of 0.49 million.
Sponsored
RYTM Stock Performance and Moving Averages
In recent trading, Rhythm Pharmaceuticals Inc (RYTM) stock price has shown some volatility, fluctuating 6.41% over the last five trades and 16.35% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 29.92%, and it has gained 26.10% in the previous three months. Currently, RYTM is trading at 8.11%, 9.85%, and 21.39% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, RYTM, a Healthcare sector stock, is trading -5.10% below its 52-week high but remains 151.79% above its 52-week low. The Average True Range (ATR) (14 days) of 2.28 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Rhythm Pharmaceuticals Inc’s Profitability and Valuation Ratios
Rhythm Pharmaceuticals Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -260.93% and a profit margin of -256.15%, with a gross margin of 29.92%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Rhythm Pharmaceuticals Inc’s market capitalization stands at $3.23 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 31.71, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 81.99, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 10.76% of Rhythm Pharmaceuticals Inc (RYTM)’s shares, while financial institutions hold 104.35%.
Notable insider trades include GOOD JENNIFER L, Director at Rhythm Pharmaceuticals Inc (RYTM), who sold 31751 shares on Sep 17 ’24, at $52.4 each, totaling $1.66 million. On Sep 09 ’24, Cramer Pamela J., Chief Human Resources Officer, sold 4099 shares for $50.03 each, amounting to $0.21 million. Additionally, on Sep 10 ’24, TETRAULT LYNN A. sold 17501 shares at $49.65 each, generating $0.87 million.
